CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Contract Liability (Deferred Revenue)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) had Contract Liability (Deferred Revenue) of $203.03 million as of 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-05
- 2026-06-27: Contract with Customer, Liability, Current $203.03M.
- 2026-03-28: Contract with Customer, Liability, Current $194.33M.
- 2025-12-27: Contract with Customer, Liability, Current $210.42M.
- 2025-09-27: Contract with Customer, Liability, Current $237.73M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-27 | $203.03M 10-Q · filed 2026-08-05 |
| 2026-03-28 | $194.33M 10-Q · filed 2026-05-07 |
| 2025-12-27 | $210.42M 10-Q · filed 2026-08-05 |
| 2025-09-27 | $237.73M 10-Q · filed 2025-11-05 |
| 2025-06-28 | $268.34M 10-Q · filed 2025-08-06 |
| 2025-03-29 | $250.46M 10-Q · filed 2025-05-07 |
| 2024-12-28 | $248.32M 10-K · filed 2026-02-18 |
| 2024-09-28 | $251.97M 10-Q · filed 2024-11-06 |
| 2024-06-29 | $247.18M 10-Q · filed 2024-08-07 |
| 2024-03-30 | $256.38M 10-Q · filed 2024-05-09 |
| 2023-12-30 | $241.82M 10-K · filed 2025-02-19 |
| 2023-09-30 | $250.49M 10-Q · filed 2023-11-08 |
| 2023-07-01 | $257.40M 10-Q · filed 2023-08-09 |
| 2023-04-01 | $262.23M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $264.26M 10-K · filed 2024-02-14 |
| 2022-09-24 | $251.47M 10-Q · filed 2022-11-02 |
| 2022-06-25 | $242.08M 10-Q · filed 2022-08-03 |
| 2022-03-26 | $228.26M 10-Q · filed 2022-05-04 |
| 2021-12-25 | $219.70M 10-K · filed 2023-02-22 |
| 2021-09-25 | $221.73M 10-Q · filed 2021-11-03 |
| 2021-06-26 | $231.33M 10-Q · filed 2021-08-04 |
| 2021-03-27 | $213.03M 10-Q · filed 2021-05-04 |
| 2020-12-26 | $207.94M 10-K · filed 2022-02-16 |
| 2020-09-26 | $172.34M 10-Q · filed 2020-10-29 |
| 2020-06-27 | $170.41M 10-Q · filed 2020-08-05 |
| 2020-03-28 | $178.83M 10-Q · filed 2020-05-07 |
| 2019-12-28 | $171.81M 10-K · filed 2021-02-17 |
| 2019-09-28 | $166.09M 10-Q · filed 2019-11-06 |
| 2019-06-29 | $167.53M 10-Q · filed 2019-07-31 |
| 2019-03-30 | $137.89M 10-Q · filed 2019-05-07 |
| 2018-12-29 | $145.14M 10-K · filed 2020-02-11 |
| 2018-09-29 | $140.76M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $130.39M 10-Q · filed 2018-08-08 |
| 2017-12-30 | $117.57M 10-K · filed 2019-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |